Beyond Air® Preannounces Preliminary Revenue for the Quarter Ended September 30, 2026
Beyond Air, Inc. (XAIR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Beyond Air ® Preannounces Preliminary Revenue for the Quarter Ended September 30, 2026 Preliminary revenue of $2.3 million represents the highest quarterly revenue reported, and approximately 30% sequential quarterly growth and 27% growth over the same period last ye
How this was made
The 30-second read
Why it matters
The company reaffirmed guidance while stating the second-generation LungFit PH remains under FDA review, implying upside depends on regulatory approval timing and continued hospital adoption.
Market read
This is a fresh quarterly revenue datapoint plus reaffirmed CY2026 and CY2027 revenue guidance, which can shift near-term expectations for a small-cap medical device name.
What to watch
Traders may focus on the gap between first-generation momentum and the pace of PMA supplement progress, plus the risk that final reported revenue diverges from the preliminary estimate.
Background
Beyond Air filed an 8-K with Item 2.02 results of operations and Item 7.01 Regulation FD disclosure, providing preliminary unaudited revenue for the quarter ended September 30, 2026 and guidance details.
Ticker impact
Beyond Air preannounces preliminary Q3 2026 revenue of about $2.3M and reaffirmed CY2026 guidance of $8M and CY2027 guidance of $16M-$18M.
Likely upward bias as traders price continued first-generation adoption, tempered by uncertainty around FDA approval timing for the second-generation system.
The filing provides a fresh quarterly revenue datapoint plus reaffirmed multi-year guidance, while explicitly noting the second-generation system is still under FDA review.
Market effects
Reinforces demand signals for nitric-oxide delivery devices and the market’s focus on FDA review milestones for next-generation systems.
No clear regional spillover beyond US small-cap biotech/medical device sentiment.
Limited, as the disclosure is company-specific and tied to US FDA review and US hospital adoption.
Counterpoint
The preliminary revenue is unaudited and the second-generation system is still under FDA review, so the market may discount the guidance until regulatory timing becomes clearer.
Key entities
- issuerBeyond Air, Inc.
Commercial-stage nitric oxide delivery medical device and biopharmaceutical company.
- productLungFit PH
Cylinder-free nitric oxide delivery system; first-generation is FDA-approved, second-generation is under FDA review.
- regulatorFDA
Reviewing the PMA supplement for the second-generation LungFit PH.
